{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-005528","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2022-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.828160+00:00","generated_at":"2026-06-26T08:30:35.122623+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Spruce Biosciences amends CEO Szwarcberg's equity vesting acceleration terms","bullets":["Amendment to CEO Javier Szwarcberg's offer letter dated April 6, 2022.","Vesting acceleration under Severance Plan for Second Stock Option now only applies to Change in Control with effective date on or after January 3, 2023.","All other terms and conditions of the offer letter remain unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-005528","json":"https://secwatch.observer/filing/0000950170-22-005528.json","markdown":"https://secwatch.observer/filing/0000950170-22-005528.md","text":"https://secwatch.observer/filing/0000950170-22-005528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017022005528/0000950170-22-005528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017022005528/sprb-20220406.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T08:30:35.122623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}